Pulmonary Surfactant Market Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Forecast Analysis to 2026

 

Pulmonary surfactant is a complex mixture of phospholipids and proteins that creates a unique interface separating alveolar gas and liquids at the alveolar cell surface, reducing surface tension, and maintaining lung volumes at end expiration. Reduction of the surface tension at the air–liquid interface is a requirement for respiratory function following birth. Deficiency of pulmonary surfactant causes respiratory failure in premature infants, or infantile respiratory distress syndrome (IRDS). The adequacy of pulmonary surfactant is maintained by unique and highly regulated systems mediating the synthesis, secretion, reutilization, and catabolism of surfactant. Loss or inactivation of pulmonary surfactant later in life occurs in the adult respiratory distress syndrome (ARDS), a significant cause of morbidity and mortality following infection, shock, or trauma. Mutations in genes regulating surfactant homeostasis, including SFTPA, SFTPB, SFTPC, ABCA3, TITF1, and CSF2RA cause acute and/or chronic lung disease in newborn infants, children, and adults. Disorders of GM-CSF signaling inhibit surfactant lipid and protein catabolism by alveolar macrophage causing pulmonary alveolar proteinosis (PAP).

Global pulmonary surfactant market size was valued at US$ 578.7  million in 2022 and is expected to witness a CAGR of 4.50 % over the forecast period (2022 – 2030).

Pulmonary Surfactant Market-Drivers

Increasing preference of animal derived surfactant for the treatment of respiratory distress syndrome is driving the pulmonary surfactant market growth over the forecast period.

Increasing preference of animal derived surfactant for the treatment of respiratory distress syndrome is driving the pulmonary surfactant market growth over the forecast period. For instance, in May 2021, according to the article published in Archives of Clinical and Medical Case Reports, an open access, peer reviewed Journal, Poractant alfa (Curosurf), significantly reduced the rates of pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung) in preterm infants with respiratory distress syndrome. This reduction was more significant in VLBW (very low birth weight) than non-VLBW (very low birth weight) infants.

Furthermore, on April 11, 2022, an article was published in National Center for Biotechnology Information, a branch of the National Institutes of Health, which reported that when animal derived pulmonary surfactant is combined with budesonide, a corticosteroid or steroid, in the treatment of neonatal respiratory distress syndrome can effectively shorten the hospital stay and reduce the time of invasive mechanical ventilation and the incidence of BPD (bronchopulmonary dysplasia). Meanwhile, it does not increase the risk of related complications or death. This approach can be applied clinically.